androgen receptor ar via proteolysis targeting chimeras protacs clinical trial intelligence

A Phase I/II, Modular, Open-Label, Multi-Centre Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD9750 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Metastatic Prostate Cancer (ANDROMEDA)

The ANDROMEDA trial, sponsored by AstraZeneca, is a pivotal Phase I/II study evaluating AZD9750, an innovative AR-PROTAC, for the treatment of metastatic prostate cancer. Given the increasing prevalence of prostate cancer and the limitations of current therapies, AZD9750 represents a potentially significant advancement in the therapeutic landscape. The modular design allows for flexible exploration of monotherapy and combination strategies, particularly with saruparib, a PARP inhibitor. The trial's success could position AstraZeneca favorably against competitors in the prostate cancer space, particularly those focusing on AR-targeted therapies. The estimated enrollment of 300 participants and the ongoing recruitment across multiple global sites underscore the strategic importance of this asset in AstraZeneca's oncology portfolio.

Matched by target_normalized: Androgen Receptor (AR) via Proteolysis-targeting Chimeras (PROTACs)